Pharmline, Zycal Partner on Ostinol

FLORIDA, N.Y.Pharmline Inc. announced an agreement with Zycal Bioceuticals Inc., Southborough, Mass., to market Ostinol, a natural osteoinductive protein complex, for use in dietary supplement applications. Zycal developed the ingredient, which contains bone morphogenetic proteins (BMPs) to activate and transform stem cells into osteoblasts and chondroblasts for bone and cartilage growth. BMPs have been used surgically and orally for this function.

By inducing the transformation of stem cells into osteoblasts and chondroblasts, Ostinol represents a totally new approach to bone and joint health and we are really excited to bring to the market a real innovation in these categories," said Greg Berthomieu, brand manager at Pharmline. These segments of our industry are dominated by building blocks ingredients like calcium for bone health or glucosamine and chondroitin for joint formulas as well as natural anti-inflammatory products that work on pain management. It is very interesting and exciting to present a new ingredient whose mode of action is based on completely different principles. Furthermore, as newly formed osteoblasts and chondroblasts will use calcium, chondroitin and other building blocks to produce new bone and cartilage tissues, Ostinol does not replace existing formulas but rather has a synergetic effect with potential combinations of tremendous value."

The companies will host a Webinar about Ostinol on Oct. 5, and will present a VendorWorks session at SupplySide West in Las Vegas. For more information, contact Pharmline at [email protected].